0001209191-14-078009.txt : 20141229
0001209191-14-078009.hdr.sgml : 20141225
20141229060531
ACCESSION NUMBER: 0001209191-14-078009
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20141223
FILED AS OF DATE: 20141229
DATE AS OF CHANGE: 20141229
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SYDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KANIA EDWIN M JR
CENTRAL INDEX KEY: 0001255927
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 141310584
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-12-23
0
0001280600
ACCELERON PHARMA INC
XLRN
0001255927
KANIA EDWIN M JR
C/O FLAGSHIP VENTURES, 1 MEMORIAL DRIVE
CAMBRIDGE
MA
02142
1
0
0
0
Common Stock
2014-12-23
4
S
0
51163
38.00
D
0
I
See Footnote
Common Stock
2014-12-23
4
S
0
3187
38.00
D
0
I
See Footnote
Common Stock
500420
I
See Footnote
Common Stock
30248
I
See Footnote
Common Stock
13136
I
See Footnote
Common Stock
251
I
See Footnote
Common Stock
28734
D
The price reported in Column 4 is a weighted average price. These shares were disposed of by OneLiberty Ventures 2000, L.P. ("OLV") and OneLiberty Advisors Fund 2000, L.P. ("OLA") in multiple transactions on the Transaction Date at prices ranging from $37.99 to $38.05, inclusive. The reporting person undertakes to provide to Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing price range.
These shares were held directly by OLV. OneLiberty Partners 2000, LLC ("OLP") is the general partner of OLV. Edwin M. Kania, Jr. is the managing member of OLP and, accordingly, may be deemed to have beneficial ownership with respect to all shares held by OLV. Mr. Kania disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
These shares were held directly by OLA. OLP is the general partner of OLA. As managing member of OLP, Edwin M. Kania, Jr. may be deemed to have beneficial ownership with respect to all shares held by OLA. Mr. Kania disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
These shares are held directly by Applied Genomic Technology Capital Fund, L.P. ("AGTC Fund"). NewcoGen Group, Inc. ("NewcoGen Inc.") is the sole general partner of AGTC Partners, L.P. ("AGTC Partners"), which is the sole general partner of AGTC Fund. NewcoGen Inc. is a wholly-owned subsidiary of Flagship Ventures Management, Inc. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the directors of Flagship Ventures Management, Inc. and, accordingly, may be deemed to have beneficial ownership with respect to all shares held by AGTC Fund. Each of Mr. Kania and Dr. Afeyan disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
These shares are held directly by AGTC Advisors Fund, L.P ("AGTC Advisors"). NewcoGen Inc. is the sole general partner of AGTC Partners, which is the sole general partner of AGTC Advisors. NewcoGen Inc. is a wholly-owned subsidiary of Flagship Ventures Management, Inc. As the directors of Flagship Ventures Management, Inc., Noubar B. Afeyan Ph.D. and Edwin M. Kania, Jr. may be deemed to have beneficial ownership with respect to all shares held by AGTC Advisors. Each of Mr. Kania and Dr. Afeyan disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
These shares are held by NewcoGen Group LLC. NewcoGen Inc. is the manager of NewcoGen Group LLC and is a wholly-owned subsidiary of Flagship Ventures Management, Inc. As the directors of Flagship Ventures Management, Inc., Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. may be deemed to have beneficial ownership with respect to all shares held by NewcoGen Group LLC. Each of Mr. Kania and Dr. Afeyan disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
These shares are held directly by AGTC Partners. NewcoGen Inc. is the general partner of AGTC Partners. NewcoGen Inc. is a wholly-owned subsidiary of Flagship Ventures Management, Inc. As the directors of Flagship Ventures Management, Inc., Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. may be deemed to have beneficial ownership with respect to all shares held by AGTC Partners. Each of Mr. Kania and Dr. Afeyan disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
/s/Edwin M. Kania, Jr.
2014-12-24